| 26.39 1.14 (4.51%) | 04-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 37.04 | 1-year : | 42.34 |
| Resists | First : | 31.71 | Second : | 36.25 |
| Pivot price | 26.91  |
|||
| Supports | First : | 24.38 | Second : | 20.28 |
| MAs | MA(5) : | 25.69 |
MA(20) : | 28.45 |
| MA(100) : | 23.73 |
MA(250) : | 19 |
|
| MACD | MACD : | -1.1 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 16.8 |
D(3) : | 8.4 |
| RSI | RSI(14): 43.8 |
|||
| 52-week | High : | 36.25 | Low : | 9.43 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ FDMT ] has closed above bottom band by 38.8%. Bollinger Bands are 42.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 26.94 - 27.04 | 27.04 - 27.16 |
| Low: | 24.31 - 24.41 | 24.41 - 24.53 |
| Close: | 26.18 - 26.36 | 26.36 - 26.57 |
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Thu, 18 Apr 2024
4d Molecular Therapeutics exec sells $45k in stock - Investing.com Australia
Mon, 15 Apr 2024
4D Molecular Therapeutics new overweight at Barclays on genetic medicine platform - Seeking Alpha
Mon, 15 Apr 2024
Institutional owners may ignore 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) recent US$83m market cap decline ... - Simply Wall St
Thu, 04 Apr 2024
4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott B - GuruFocus.com
Thu, 04 Apr 2024
4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares - Yahoo Finance
Sun, 03 Mar 2024
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Consensus Forecasts Have Become A Little Darker Since Its Latest ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 3.197e+007 (%) |
| Held by Institutions | 3.5 (%) |
| Shares Short | 8,340 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.0866e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 192 % |
| Return on Assets (ttm) | 905.2 % |
| Return on Equity (ttm) | -23.5 % |
| Qtrly Rev. Growth | 2.072e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -13.08 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -76 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0.5 |
| Price to Book value | 0 |
| Price to Sales | -2.02 |
| Price to Cash Flow | 10.55 |
| Dividend | 0 |
| Forward Dividend | 9.32e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|